陇神戎发：2025年前三季度净利润约2703万元，同比增加8.11%

Group 1 - Company LongShen RongFa reported Q3 performance with revenue of approximately 647 million yuan, a year-on-year decrease of 16.12% [1] - The net profit attributable to shareholders was approximately 27.03 million yuan, an increase of 8.11% year-on-year [1] - Basic earnings per share were 0.0891 yuan, reflecting an increase of 8.13% year-on-year [1] Group 2 - The market capitalization of LongShen RongFa is currently 3.1 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion USD this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market faces challenges in fundraising [2]